Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia. The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations...

DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3 inhibition, or inhibiting the interactions of CBFB with RUNX1 and RUNX3 could help treat neurofibromatosis. In mouse neurofibroma Schwann...

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...

A study published in Nature Communications suggests cyclin dependent kinase 6, a known molecular target for cancer, could also be targeted to treat obesity and metabolic diseases. White adipose tissue (WAT) stores energy in rodents...

INDICATION: Acute myelogenous leukemia (AML) Patient samples, cell culture, and mouse studies suggest inhibiting RUNX1 could help treat AML with FLT3 mutations. In AML patients, RUNX1 expression was higher in leukemia samples from patients with...

In a paper published in The Journal of Experimental Medicine , European scientists showed that tumor suppressor runt-related transcription factor 1 (RUNX1) works cooperatively with FMS-like tyrosine kinase 3 (FLT3; CD135)-internal tandem duplication (ITD) mutations to...

Cancer INDICATION: Acute myelogenous leukemia (AML) In vitro, mouse and patient sample studies suggest a small molecule protein-protein inhibitor could help treat the inv(16) subtype of AML. The subtype is driven by an oncogenic CBFB-SMMHC...